


**Product Name** : JNJ-63576253  
**Cat. No.** : PC-72511  
**CAS No.** : 2110428-64-1  
**Molecular Formula** : C<sub>23</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>S  
**Molecular Weight** : 538.974  
**Target** : Androgen Receptor (AR)  
**Solubility** : 10 mM in DMSO



## Biological Activity

JNJ-63576253 (TRC-253, JNJ63576253) is a next-generation, potent, selective **androgen receptor (AR)** antagonist (inhibitor) against wild-type AR (IC<sub>50</sub>=6.9 nM), AR F877L and other clinically detected ligand binding domain (LBD) point mutations.

JNJ-63576253 inhibits transcriptional activity in reporter assays, cellular proliferation, and AR downstream target gene expression.

JNJ-63576253 causes tumor growth inhibition (TGI) in an enzalutamide-resistant LNCaP F877 L xenograft model.

JNJ-63576253 displayed an approximately 1,000-fold selectivity versus other nuclear hormone receptors (GR IC<sub>50</sub>>30 uM).

JNJ-63576253 completely inhibited transiently transfected VP16-AR F877 L with IC<sub>50</sub> of 15 nM in HepG2 transcriptional reporter models, JNJ-63576253 completely inhibited AR-mediated transactivation in the presence of 100 pmol/L R1881 (IC<sub>50</sub>=99 nM).

JNJ-63576253 abrogates cellular proliferation, nuclear translocation, and AR target gene expression in models of human prostate adenocarcinoma.

JNJ-63576253 causes tumor growth inhibition (TGI) in an enzalutamide-resistant LNCaP F877 L xenograft model.

## References

Zhang Z, et al. *J Med Chem*. 2021 Jan 28;64(2):909-924.

Branch JR, et al. *Mol Cancer Ther*. 2021 May;20(5):763-774.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com